IncellDx, Inc. is a single cell diagnostic company committed to advancing Precision Medicine by offering transformative diagnostic and prognostic clinical patient information based on an innovative technology platform that enables simultaneous cell classification and single cell analysis of proteomic and genomic biomarkers.
Recognizing every cell tells a story we are dedicated to revolutionizing healthcare one cell at a time. Combining proprietary molecular diagnostics with cellular analysis, we offer diagnostic, prognostic and therapeutic clinical information for physicians to make more informed clinical decisions.
HPV OncoTect 3Dx™
More than 450,000 new cases of cervical cancer are diagnosed each year. Our CE-IVD HPV OncoTect 3Dx™ for in vitro diagnostics is a unique quantative cell based assay that measures both mRNA E6 and E7.
The First Diagnostic Test for Long COVID Will Formally Launch in Europe in September
The IncellDx incellKINE Long COVID In Vitro Diagnostic Receives European CE Marking for Its In Vitro Diagnostic (IVD) for Long COVID
IncellDx’s Next Gen HPV/Cervical Cancer Assay (HPV OncoTect 3Dx) Receives Clinical Approval from Costa Rican Ministry of Health
IncellDx’s abstract has been accepted to ASCO Genitourinary Cancers Symposium 2019.
February 14-16, 2019.
IncellDx presents abstracts at IPVC 2018 in Australia.
HPV OncoTect 3Dx Clinical Reproducibility
Co-expression of E6, E7 mRNA and PD-L1 in Cervical Samples